Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Spinal Muscular Atrophy Type I
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
Study leads
May Orfali, MD
Study Director
Gemma Biotherapeutics